| [1] | Medical Research Council (1948) Streptomycin treatment of pulmonary tuberculosis. BMJ 2: 769–782.
|
| [2] | Mitchison DA (2005) The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 171: 699–706.
|
| [3] | Fox W, Ellard GA, Mitchison DA (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3: S231–S279.
|
| [4] | Mitchison DA, Nunn AJ (1986) Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 133: 423–430.
|
| [5] | David H (1970) Probability distribution of drug-resistant mutants in unselected populations of . Appl Microbiol 20: 810–814.
|
| [6] | Centers for Disease Control and Prevention (2003) Treatment of tuberculosis. MMWR Recomm Rep 52: 1–77.
|
| [7] | Wallis RS, Patil S, Cheon SH, Edmonds K, Phillips M, et al. (1999) Drug tolerance in . Antimicrob Agents Chemother 43: 2600–2606.
|
| [8] | Mitchison DA (1979) Basic mechanisms of chemotherapy. Chest 76: 771–781.
|
| [9] | Paramasivan CN, Sulochana S, Kubendiran G, Venkatesan P, Mitchison DA (2005) Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of . Antimicrob Agents Chemother 49: 627–631.
|
| [10] | Herbert D, Paramasivan CN, Venkatesan P, Kubendiran G, Prabhakar R, et al. (1996) Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of . Antimicrob Agents Chemother 40: 2296–2299.
|
| [11] | Jindani A, Aber VR, Edwards EA, Mitchison DA (1980) The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 121: 939–949.
|
| [12] | Hobby GL, Holman AP, Iseman MD, Jones JM (1973) Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis. Antimicrob Agents Chemother 4: 94–104.
|
| [13] | Heifets L, Lindholm-Levy P (1992) Pyrazinamide sterilizing activity in vitro against semidormant bacterial populations. Am Rev Respir Dis 145: 1223–1225.
|
| [14] | Hu Y, Coates AR, Mitchison DA (2006) Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant . Int J Tuberc Lung Dis 10: 317–322.
|
| [15] | Levin BR, Rozen DE (2006) Non-inherited antibiotic resistance. Nat Rev Microbiol 4: 556–562.
|
| [16] | Dhar N, McKinney JD (2007) Microbial phenotypic heterogeneity and antibiotic tolerance. Curr Opin Microbiol. E-pub 8 January 2006.
|
| [17] | Lewis K (2007) Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5: 48–56.
|
| [18] | Chiang CY, Riley LW (2005) Exogenous reinfection in tuberculosis. Lancet Infect Dis 5: 629–636.
|
| [19] | Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, et al. (2005) Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 171: 1430–1435.
|
| [20] | Centers for Disease Control and Prevention (2006) Emergence of with extensive resistance to second-line drugs—worldwide, 2000–2004. MMWR Morb Mortal Wkly Rep 55: 301–305.
|
| [21] | Gandhi NR, Moll A, Pawinski R, Sturm AW, Lalloo U, et al. (2006) Extensively drug-resistant (XDR) tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368: 1575–1580.
|
| [22] | Cox H, Kebede Y, Allamuratova S, Ismailov G, Davletmuratova Z, et al. (2006) Tuberculosis recurrence and mortality after successful treatment: Impact of drug resistance. PLoS Med 3: e384. doi:10.1371/journal.pmed.0030384.
|
| [23] | Canetti G (1955) The tubercle bacillus in the pulmonary lesion of man: Histobacteriology and its bearing on the therapy of pulmonary tuberculosis. New York: Springer Publishing Company.
|
| [24] | Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, et al. (2003) growth at the cavity surface: A microenvironment with failed immunity. Infect Immun 71: 7099–7108.
|
| [25] | Vandiviere HM, Loring WE, Melvin I, Willis S (1956) The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection. Am J Med Sci 232: 30–37.
|
| [26] | Opie EL, Aronson JD (1927) Tubercle bacilli in latent tuberculosis lesions and in lung tissue without tuberculosis lesions. Arch Pathol Lab Med 4: 1–21.
|
| [27] | Hernandez-Pando R, Jeyanathan M, Mengistu G, Aguilar D, Orozco H, et al. (2000) Persistence of DNA from in superficially normal lung tissue during latent infection. Lancet 356: 2133–2138.
|
| [28] | Di Perri G, Cazzadori A, Vento S, Bonora S, Malena M, et al. (1996) Comparative histopathological study of pulmonary tuberculosis in human immunodeficiency virus-infected and non-infected patients. Tuber Lung Dis 77: 244–249.
|
| [29] | Boshoff HI, Barry CE 3rd (2005) Tuberculosis—Metabolism and respiration in the absence of growth. Nat Rev Microbiol 3: 70–80.
|
| [30] | Flynn JL, Chan J (2001) Tuberculosis: Latency and reactivation. Infect Immun 69: 4195–4201.
|
| [31] | Gomez JE, McKinney JD (2004) persistence, latency, and drug tolerance. Tuberculosis (Edinb) 84: 29–44.
|
| [32] | Hingley-Wilson SM, Sambandamurthy VK, Jacobs WR Jr (2003) Survival perspectives from the world's most successful pathogen, . Nat Immunol 4: 949–955.
|
| [33] | Parrish NM, Dick JD, Bishai WR (1998) Mechanisms of latency in . Trends Microbiol 6: 107–112.
|
| [34] | Boon C, Dick T (2002) BCG response regulator essential for hypoxic dormancy. J Bacteriol 184: 6760–6767.
|
| [35] | Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, et al. (2003) Inhibition of respiration by nitric oxide induces a dormancy program. J Exp Med 198: 705–713.
|
| [36] | Voskuil MI, Visconti KC, Schoolnik GK (2004) gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis (Edinb) 84: 218–227.
|
| [37] | Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, et al. (2001) Regulation of the hypoxic response gene encoding alpha-crystallin. Proc Natl Acad Sci U S A 98: 7534–7539.
|
| [38] | Barclay WR, Ebert RH, Le Roy GV, Manthei RW, Roth LJ (1953) Distribution and excretion of radioactive isoniazid in tuberculous patients. J Am Med Assoc 151: 1384–1388.
|
| [39] | Allen BW, Mitchison DA (1992) Counts of viable tubercle bacilli in sputum related to smear and culture gradings. Med Lab Sci 49: 94–98.
|
| [40] | International Union Against Tuberculosis Committee on Prophylaxis (1982) Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. Bull World Health Organ 60: 555–564.
|
| [41] | Walgreen A (1948) The time-table of tuberculosis. Tubercle 29: 245–251.
|
| [42] | Munoz-Elias EJ, Timm J, Botha T, Chan WT, Gomez JE, et al. (2005) Replication dynamics of in chronically infected mice. Infect Immun 73: 546–551.
|
| [43] | Rees RJ, Hart PD (1961) Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. Br J Exp Pathol 42: 83–88.
|
| [44] | McCune RM Jr, Tompsett R (1956) Fate of in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med 104: 737–762.
|
| [45] | Stewart PS (2002) Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 292: 107–113.
|
| [46] | Warner DF, Mizrahi V (2006) Tuberculosis chemotherapy: The influence of bacillary stress and damage response pathways on drug efficacy. Clin Microbiol Rev 19: 558–570.
|
| [47] | McDermott W (1958) Microbial persistence. Yale J Biol Med 30: 257–291.
|
| [48] | Eagle H (1949) The effect of the size of the inoculum and the age of the infection on the curative dose of penicillin in experimental infections with streptococci, pneumococci, and . J Exp Med 90: 595–607.
|
| [49] | Eagle H (1952) Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 13: 389–399.
|
| [50] | Bigger J (1944) Treatment of staphylococcal infections with penicillin by intermittent sterilisation. Lancet 247: 497–500.
|
| [51] | Wiuff C, Zappala RM, Regoes RR, Garner KN, Baquero F, et al. (2005) Phenotypic tolerance: Antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob Agents Chemother 49: 1483–1494.
|
| [52] | Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S (2004) Bacterial persistence as a phenotypic switch. Science 305: 1622–1625.
|
| [53] | Barker J, Scaife H, Brown MR (1995) Intraphagocytic growth induces an antibiotic-resistant phenotype of . Antimicrob Agents Chemother 39: 2684–2688.
|
| [54] | Lewis K (2005) Persister cells and the riddle of biofilm survival. Biochemistry (Mosc) 70: 267–274.
|
| [55] | Debbia EA, Roveta S, Schito AM, Gualco L, Marchese A (2001) Antibiotic persistence: The role of spontaneous DNA repair response. Microb Drug Resist 7: 335–342.
|
| [56] | Miller C, Thomsen LE, Gaggero C, Mosseri R, Ingmer H, et al. (2004) SOS response induction by beta-lactams and bacterial defense against antibiotic lethality. Science 305: 1629–1631.
|
| [57] | Keren I, Shah D, Spoering A, Kaldalu N, Lewis K (2004) Specialized persister cells and the mechanism of multidrug tolerance in . J Bacteriol 186: 8172–8180.
|
| [58] | Shah D, Zhang Z, Khodursky A, Kaldalu N, Kurg K, et al. (2006) Persisters: A distinct physiological state of . BMC Microbiol 6: 53.
|
| [59] | Buts L, Lah J, Dao-Thi MH, Wyns L, Loris R (2005) Toxin-antitoxin modules as bacterial metabolic stress managers. Trends Biochem Sci 30: 672–679.
|
| [60] | Gerdes K, Christensen SK, Lobner-Olesen A (2005) Prokaryotic toxin-antitoxin stress response loci. Nat Rev Microbiol 3: 371–382.
|
| [61] | Arcus VL, Rainey PB, Turner SJ (2005) The PIN-domain toxin-antitoxin array in mycobacteria. Trends Microbiol 13: 360–365.
|
| [62] | Zhu L, Zhang Y, Teh JS, Zhang J, Connell N, et al. (2006) Characterization of mRNA interferases from . J Biol Chem 281: 18638–18643.
|
| [63] | Korch SB, Henderson TA, Hill TM (2003) Characterization of the hipA7 allele of and evidence that high persistence is governed by (p)ppGpp synthesis. Mol Microbiol 50: 1199–1213.
|
| [64] | Dahl JL, Kraus CN, Boshoff HI, Doan B, Foley K, et al. (2003) The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of in mice. Proc Natl Acad Sci U S A 100: 10026–10031.
|
| [65] | Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: A common cause of persistent infections. Science 284: 1318–1322.
|
| [66] | Spoering AL, Lewis K (2001) Biofilms and planktonic cells of have similar resistance to killing by antimicrobials. J Bacteriol 183: 6746–6751.
|
| [67] | Darzins E, Fahr G (1956) Cord-forming property, lethality and pathogenicity of Mycobacteria. Dis Chest 30: 642–648.
|
| [68] | Dubos RJ, Pierce CH, Schaefer WB (1956) Differential characteristics in vitro and in vivo of several substrains of BCG. III. Multiplication and survival in vivo. Am Rev Tuberc 74: 683–698.
|
| [69] | Middlebrook G, Dobos RJ, Pierce C (1947) Virulence and morphological characteristics of mammalian tubercle bacilli. J Exp Med 86: 175–184.
|
| [70] | Carter G, Young LS, Bermudez LE (2004) A subinhibitory concentration of clarithromycin inhibits biofilm formation. Antimicrob Agents Chemother 48: 4907–4910.
|
| [71] | Teng R, Dick T (2003) Isoniazid resistance of exponentially growing biofilm culture. FEMS Microbiol Lett 227: 171–174.
|
| [72] | Yamazaki Y, Danelishvili L, Wu M, Hidaka E, Katsuyama T, et al. (2006) The ability to form biofilm influences invasion and translocation of bronchial epithelial cells. Cell Microbiol 8: 806–814.
|
| [73] | Roberts ME, Stewart PS (2005) Modelling protection from antimicrobial agents in biofilms through the formation of persister cells. Microbiology 151: 75–80.
|
| [74] | Salomon JA, Lloyd-Smith JO, Getz WM, Resch S, Sanchez MS, et al. (2006) Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med 3: e273. doi:10.1371/journal.pmed.0030273.
|
| [75] | Coates AR, Hu Y (2006) New strategies for antibacterial drug design: targeting non-multiplying latent bacteria. Drugs R D 7: 133–151.
|
| [76] | Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, et al. (2005) A diarylquinoline drug active on the ATP synthase of . Science 307: 223–227.
|
| [77] | Petrella S, Cambau E, Chauffour A, Andries K, Jarlier V, et al. (2006) Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother 50: 2853–2856.
|
| [78] | [No authors listed] (1984) A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months. Am Rev Respir Dis 130: 23–28.
|
| [79] | [No authors listed] (1987) Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 136: 1339–1342.
|
| [80] | [No authors listed] (1989) A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 139: 871–876.
|
| [81] | Comstock GW, Baum C, Snider DE Jr (1979) Isoniazid prophylaxis among Alaskan Eskimos: A final report of the bethel isoniazid studies. Am Rev Respir Dis 119: 827–830.
|
| [82] | Norrby SR (1990) Short-term treatment of uncomplicated lower urinary tract infections in women. Rev Infect Dis 12: 458–467.
|
| [83] | Wolfson JS, Hooper DC, McHugh GL, Bozza MA, Swartz MN (1990) Mutants of K-12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agents. Antimicrob Agents Chemother 34: 1938–1943.
|
| [84] | DiNubile MJ (1994) Short-course antibiotic therapy for right-sided endocarditis caused by in injection drug users. Ann Intern Med 121: 873–876.
|
| [85] | Nolan CM, Beaty HN (1976) bacteremia. Current clinical patterns. Am J Med 60: 495–500.
|
| [86] | Ribera E, Gomez-Jimenez J, Cortes E, del Valle O, Planes A, et al. (1996) Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided endocarditis. A randomized, controlled trial. Ann Intern Med 125: 969–974.
|
| [87] | Small PM, Chambers HF (1990) Vancomycin for endocarditis in intravenous drug users. Antimicrob Agents Chemother 34: 1227–1231.
|
| [88] | Kaatz GW, Seo SM (1996) In vitro activities of oxazolidinone compounds U100592 and U100766 against and . Antimicrob Agents Chemother 40: 799–801.
|
| [89] | Karchmer AW (1985) Staphylococcal endocarditis. Laboratory and clinical basis for antibiotic therapy. Am J Med 78: 116–127.
|
| [90] | Korzeniowski O, Sande MA (1982) Combination antimicrobial therapy for endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med 97: 496–503.
|
| [91] | [No authors listed] (1986) Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis 133: 779–783.
|
| [92] | [No authors listed] (1988) Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis 137: 1147–1150.
|
| [93] | Dutt AK, Moers D, Stead WW (1989) Smear- and culture-negative pulmonary tuberculosis: Four-month short-course chemotherapy. Am Rev Respir Dis 139: 867–870.
|
| [94] | [No authors listed] (1991) Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/ British Medical Research Council. Am Rev Respir Dis 143: 700–706.
|
| [95] | Snider DE, Graczyk J, Bek E, Rogowski J (1984) Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis 130: 1091–1094.
|
| [96] | Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, et al. (2002) Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: A randomised clinical trial. Lancet 360: 528–534.
|
| [97] | Perriens JH, St Louis ME, Mukadi YB, Brown C, Prignot J, et al. (1995) Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 332: 779–784.
|
